Prakoeswa 2017.

Methods	Randomised double‐blind placebo‐controlled trial
Participants	22 children 0 to 14 years of age (12 probiotic and 10 placebo) with mild to moderate atopic dermatitis meeting the Hanifin‐Rajka diagnostic criteria. New outpatients from the clinic at the Allergy Immunology Division of the Dermatology and Venereology Department, Faculty of Medicine, Indonesia. Participants had to have age‐related total serum IgE levels: 10 to 15 years > 200 IU/mL, 6 to 9 years > 90 IU/mL, 1 to 5 years > 60 IU/mL, < 1 year > 1.5 IU/mL. Participants had to be in apparent good health and willing to participate in the study, and had to sign informed consent Exclusion criteria: use of systemic corticosteroids or phototherapy in the previous month, systemic immunosuppressive drugs in the previous 3 months, probiotic use in the previous 4 weeks, use of topical medications such as corticosteroids or calcineurin inhibitors in the previous week, immunosuppressive conditions or other serious disease, clinical skin disease, and other systemic disease Country: Indonesia
Interventions	Intervention: microencapsulated L plantarum IS‐10506 at a dose of 10¹º CFUs/d Control: placebo; skim milk ‐ Avicel Duration: 12 weeks
Outcomes	SCORAD score at 0, 2, 8, and 14 weeks Total IgE, IL‐4, IFN‐γ, Foxp3=/IL‐10, IL‐17 at 0 and 14 weeks
Notes	‐

AAF: amino acid‐based formula.
 CC: Clostridium coccidioides.
 CFU: colony‐forming unit.
 CGI: Clinical Global Impression.
 ER: Eubacterium rectale.
 IFN: interferon.
 IgE: immunoglobulin E.
 IL: interleukin.
 SCFA: short‐chain fatty acid.
 SCORAD: Severity Scoring of Atopic Dermatitis.